Epacadostat clinical trials

A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

This study looks at new treatments for a type of head and neck cancer that has come back or spread. It compares an immunotherapy drug called pembrolizumab, alone or with another drug called epacadostat, against a standard treatment.